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Background: Epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors have been introduced in the standard therapy of
non–small-cell lung cancer (NSCLC), but they benefit a minority
of patients. The study of molecular markers may identify the subset
of patients who are the most appropriate to treat with these agents.
Methods: We analyzed 43 patients with advanced NSCLC who
were treated with gefitinib, an oral EGFR tyrosine kinase inhibitor,
were included in analysis. We evaluated EGFR in tumor tissue by
using immunohistochemistry and fluorescence in situ hybridization.
We also studied downstream molecules (AKT, ERK, p38 MAPK)
and their activation status and the presence of EGFR mutations in
tumor tissue in exons 18-21.
Results: Three patients had tumors with EGFR mutations, all of
which had EGFR gene amplification with a ratio of 2 or greater
(p  0.001). There was no correlation between EGFR protein
expression and gene amplification. Six patients (14%) achieved an
objective response and nine (21%) had stable disease; the median
survival was 162 days. EGFR mutations, high levels of AKT protein
expression, rash of any grade, and no history of smoking were
predictive of disease control (objective response plus stable disease).
Only 3 of 15 patients (20%) with disease control had an EGFR
mutation. On multivariate analysis, rash and AKT were independent
predictors of disease control. Patients with rash survived longer than
patients without rash.
Conclusions: EGFR mutation-positive tumors are present in a small
fraction of patients who achieve disease control with gefitinib. Other
molecular markers, such as AKT, need to be further evaluated.
Clinical parameters remain major determinants of gefitinib activity
in NSCLC.
Key Words: Gefitinib, Non–small-cell lung cancer, Epidermal
growth factor receptor.
(J Thorac Oncol. 2006;1: 52–60)
Lung cancer is a common and lethal malignancy thataccounts for most cancer-related deaths in the United
States and worldwide.1,2 Patients usually present at advanced
disease stages when treatment is rarely curative. With stan-
dard contemporary platinum-based chemotherapy regimens,
the median survival of patients with advanced non–small-cell
lung cancer (NSCLC) is 8 to 10 months, and 1-year survival
is approximately 40%.3 In recent years, the introduction of
novel molecular targeted agents, including the epidermal
growth factor receptor (EGFR) inhibitors, has significantly
altered the way we view and treat NSCLC. EGFR is a
member of the EGFR subfamily of receptors (or erbB ty-
rosine kinase receptors) that is critical for the growth of many
epithelial malignancies and a promising target for anticancer
therapy. The two main ways of targeting this important
molecule are with tyrosine kinase inhibitors, such as erlotinib
and gefitinib, which block the ATP-binding site in the cell
cytoplasm, and with monoclonal antibodies against the EGFR
receptor, such as cetuximab. Gefitinib and erlotinib have been
approved by the Food and Drug Administration in the United
States for the treatment of previously treated NSCLC. How-
ever, only a small percentage of patients with advanced
NSCLC, approximately 10 to 20%, achieves objective re-
sponses with EGFR-tyrosine kinase inhibitors (EGFR-
TKIs).4–6 Surprisingly, reliable molecular biomarkers that
predict benefit from EGFR-targeted therapy have been elu-
sive. Although EGFR is expressed in most NSCLC tumors
and originally supported the rationale for the study of EGFR
inhibitors in this disease, the level of expression of EGFR has
not been shown to be a predictor of clinical response to
EGFR-TKIs.7,8 There is a need to identify patients that are
*Division of Hematology-Oncology, Department of Medicine and †Depart-
ment of Pathology, Northwestern University Feinberg School of Medi-
cine and the Robert H. Lurie Comprehensive Cancer Center of North-
western University, Chicago, Illinois; ‡Evanston Northwestern
Healthcare, Evanston, Illinois; §Helen Graham Cancer Center, Newark,
Delaware; Department of Biostatistics, University of Pittsburgh, Pitts-
burgh, Pennsylvania; #School of Pharmacy, University of Wisconsin,
Madison, Wisconsin
Address correspondence to: Athanassios Argiris, M.D., Division of He-
matology-Oncology, University of Pittsburgh, UPMC Cancer Pavil-
ion, 5th Floor, 5150 Centre Ave., Pittsburgh, PA 15232. E-mail:
argirisae@upmc.edu
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0101-0052
Journal of Thoracic Oncology • Volume 1, Number 1, January 200652
most likely to benefit from these agents. The importance of
appropriate patient selection for anti-EGFR therapy was un-
derscored by the negative results of phase III randomized
trials that compared platinum doublets with or without an
EGFR-TKI in the first-line treatment of advanced NSCLC9–12
and, more recently, by the results of a randomized phase III
trial of gefitinib versus placebo in patients with previously
treated NSCLC.13 In the latter trial, although the small sur-
vival benefit shown with gefitinib did not reach statistical
significance, a significant survival advantage was seen in
selected patient subsets (non-smokers and Asians). Erlotinib,
however, resulted in a survival advantage of approximately 2
months compared with placebo in a similar study population
(BR.21 study).14 A survival benefit was seen among all
patient subgroups, but it may have been more pronounced in
patients who were lifetime non-smokers (versus current or
former smokers) and patients who had EGFR-positive tumors
(versus EGFR-negative tumors).
Recently, function-gaining somatic mutations in exons
18-21 of the EGFR gene that code for the intracellular
ATP-binding domain of the receptor and that may lead to
dramatic clinical responses to EGFR tyrosine kinase inhibi-
tors were identified.15,16 Three types of mutations have been
described: missense mutations in exons 18-21, deletions in
exon 19, and small in-frame insertions in exon 20. The most
common EGFR mutations include the E746_A750 exon 19
deletion and the missense mutation L858R in exon 21.17
Laboratory studies have demonstrated that tumor cells bear-
ing these activating EGFR mutations have increased sensi-
tivity to EGFR-TKIs.15,16 In three initial reports, EGFR mu-
tations were present in 25 of 31 patients (81%) with dramatic
responses to EGFR-TKIs; in contrast, no EGFR mutations
were present in 29 patients with EGFR-TKI–refractory
NSCLC.15,16,18 Moreover, Paez et al.16 and others have re-
ported that certain clinicopathological characteristics, such as
Japanese ethnicity, female gender, and adenocarcinomas,
which have been correlated with response to EGFR-TKIs,
also correlate with the presence of EGFR mutations.19 How-
ever, EGFR mutations are present in a relatively small frac-
tion (approximately 10%) of Caucasian patients with NSCLC
but much higher in East Asians.19–25 Clinical benefit from
EGFR-TKIs is observed in a broader patient group and is not
restricted to dramatic tumor responses. Correlating EGFR
mutations with EGFR gene amplification and other EGFR-
pathway downstream molecules is of interest. Cappuzzo et
al.26 reported that EGFR gene copy number is an independent
predictor of response to gefitinib and survival. Moreover,
Tsao et al.27 recently conducted an analysis of molecular
predictors of outcome in the BR.21 study, which compared
erlotinib with placebo in patients with previously treated
NSCLC, and found that EGFR protein expression or EGFR
copy number but not the EGFR mutational status was pre-
dictive of response to erlotinib. In addition to EGFR status,
important signaling pathways that are activated by EGFR and
may be possibly associated with the clinical antitumor activ-
ity of EGFR inhibitors include phosphatidylinositol-3 kinase
(PI3K)–AKT that relates to cell survival and the mitogen-
activated protein kinase (MAPK) that induces cell prolifera-
tion.28 To identify predictors of outcome after gefitinib ther-
apy, we conducted an analysis of molecular markers in
patients with advanced NSCLC who were treated with single-
agent gefitinib.
PATIENTS AND METHODS
We studied patients with NSCLC who were registered
on a gefitinib study protocol that was approved by North-
western University’s institutional review board. All patients
signed informed consent before study enrollment. Gefitinib
was provided on a compassionate use basis by AstraZeneca
Pharmaceuticals (Wilmington, DE). This program was avail-
able at Northwestern University (Chicago Campus and Evan-
ston Northwestern Healthcare) from December 2000 to
March 2003. A total of 188 patients were enrolled into the
study protocol. Eligibility criteria for study enrollment in-
cluded: (1) histologically or cytologically confirmed NSCLC
with locally advanced or metastatic disease (stage III or IV);
(2) disease progression after radiation or chemotherapy or
unsuitability for chemotherapy; (3) ineligibility for other
trials with gefitinib; (4) no prior treatment with gefitinib; (5)
recovery from previous surgery; (6) no other active malig-
nancies; and (7) women participants who were not pregnant
or lactating. Patients did not receive concurrent chemother-
apy, radiotherapy, or other systemic investigational agents
during the study.
After a loading dose of 500 mg on day 1, patients
received oral gefitinib 250 mg per day, which was continued
until progression or intolerable toxicity. Dose interruptions
were allowed for a maximum of 2 weeks in the event of
significant toxicity. Although not strictly mandated by the
protocol, patients were routinely assessed every 8 weeks by
using imaging tests and every 4 weeks through physical
examination and toxicity assessments; the median time to first
assessment was 8 weeks (range, 4–12 weeks). A minority of
patients who received gefitinib for prolonged periods of time
had imaging reevaluations performed every 12 weeks.
For the purpose of the present analysis, we identified
the subset of patients who had available archived tumor tissue
samples obtained from previous diagnostic or therapeutic
procedures at Northwestern University and affiliated hospi-
tals. All patients included in this study had provided consent
for the use of tumor tissue for research purposes. Pathology
slides were reviewed to document the accuracy of histologi-
cal classification. Clinical data were derived from review of
all available medical records. Variables included in the anal-
ysis were: age, gender, race, stage and sites of disease,
performance status, prior therapies, smoking history, toxici-
ties, objective response, and time of progression and/or death.
Response assessment was conducted using standard solid
tumor response criteria (RECIST).29 Responses were usually
confirmed by repeated imaging after 4 to 12 weeks. Stable
disease was defined as no tumor progression or shrinkage
meeting objective response criteria for a period of at least 8
weeks. Toxicity was graded according to a modified version
of the National Cancer Institute-Common Toxicity Criteria,
version 2.0.
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Immunohistochemistry
We tested EGFR and downstream biomarkers (AKT,
ERK, and p38 MAPK) using immunohistochemistry methods
on paraffin-embedded tissue. The activation status of EGFR
and downstream pathways was assessed using antibodies
specific for the phosphorylated state of EGFR (pEGFR),
AKT (pAKT), ERK (pERK), and p38 MAPK (pp38 MAPK).
Paraffin-embedded tumor samples were deparaffinized
and rehydrated. Antigen retrieval was performed using
EDTA solution (for pEGFR) or citrate buffer (for all others)
in a steamer for 25 minutes. In our EGFR staining procedure,
we used proteinase K for 5 minutes on the autostainer for
enzyme-induced antigen retrieval. Slides were allowed to
cool to room temperature and rinsed with tris-buffered saline
and endogenous peroxidase blocked with a 3% hydrogen
peroxide solution, followed by 5 minutes in protein block to
prevent nonspecific background staining. Primary antibody
was added to the tissue sections at room temperature on an
autostainer for 1 hour (30 minutes for EGFR assay); the slides
were rinsed and then incubated with secondary antibody.
Scoring was performed by examining the entire slide and
estimating the percentage of tumor cells exhibiting antibody
staining (see “Fluorescence In Situ Hybridization”). The
following primary antibodies were used: (1) EGFR (antibody
H11); (2) p-EGFR (cell signaling-[TYR1068] clone 1H12; it
detects EGFR only when phosphorylated at Tyr1068); (3)
AKT (cell signaling); (4) p-AKT (cell signaling; it detects
phosphorylation at Ser473); (5) ERK (cell signaling; p44/42
MAPK); (6) p-ERK (cell signaling; it detects phosphorylation
at threonine 2002 and 204); (7) p-38 (cell signaling); and (8)
p-p38 (cell signaling; it detects p38 MAPK only when acti-
vated by dual phosphorylation of Thr180/Tyr182).
We used the following cell membrane staining intensity
criteria: 0-1 (negative): no staining is observed or weak
membrane staining is in less than 10% of the tumor cells; 2
(weakly positive): a weak to moderate complete membrane
staining is observed in more than 10% of the tumor cells; and
3 (strongly positive): a strong complete membrane staining
is observed in more than 10% of the tumor cells. Cytoplasmic
and nuclear staining scoring was performed by selecting 10
random fields at 40 magnification. In each case, 50 tumor
cells were evaluated for staining intensity. For cytoplasmic
staining, the immunostaining intensity was scored on a four-
point scale where 0  no staining, 1  mild staining, 2 
moderate staining, 3  high staining. The recorded immuno-
staining score was based on the intensity of cytoplasmic
staining expressed by most interest cells in each section. For
nuclear staining intensity we used a five-tier system: 0 (com-
pletely negative cells); 1 (minimal nuclear staining); 2 (mod-
erate but incomplete nuclear staining); 3 (moderate and com-
plete nuclear staining); and 4 (strong diffuse nuclear
staining). A score of 0-1 was considered negative (or low)
and a score of 2-4 was considered positive (or high). When
a tumor exhibited both cytoplasmic and nuclear staining, the
highest score of the two was reported. Scoring of immuno-
histochemistry assays was performed without knowledge of
clinical or other laboratory information.
Fluorescence In Situ Hybridization
We used the Path Vysion EGFR DNA Probe Kit
(Vysis, Inc., Downers Grove, IL) that is designed to detect
amplification of the EGFR gene via fluorescence in situ
hybridization (FISH) in formalin-fixed, paraffin-embedded
cancer tissue specimens. One 2-mm core of viable, represen-
tative, lung cancer tissue was removed from each formalin-
fixed paraffin-embedded block and placed into a tissue mi-
croarray block (TMA). The final TMA blocks consisted of 54
cases included in four TMAs. The TMA blocks were then cut
on charged slides and deparaffinized and pretreated (Vysis
Kit #3; Vysis, Inc.) Briefly, the slides were incubated with
45% formic acid and 0.3% H2O2 at room temperature for 15
minutes; washed; pretreated (pretreatment solution, Vysis,
Inc.) at 80ºC for 10 minutes; washed; exposed for 3 minutes
to protease working solution and then exposed to protease
stop solution for 3 minutes; dehydrated in 70%, 85%, and
100% ethanol (each 1 minute); placed in Hybrid instrument
(Vysis, Inc.); and then co-denatured at 73ºC for 5 minutes.
Hybridization (EGFR/CEP 7 Dual Color Probe; Vysis, Inc.)
was performed at 37ºC overnight (17-18 hours), then the
sample was washed with post-hybridization wash solutions
(2X SSC and 0.3% MP-40; Vysis, Inc.) at room temperature
and again at 73ºC for 2 minutes. The slides were then dried
and counterstained (DAPI-1; Vysis, Inc.), cover-slipped, and
stored at 20ºC. Thirty nuclei per tumor core were counted,
and the ratio of orange to green signals was calculated. A
normal cell would be expected to have two orange (EGFR;
7p12) and two green (CEP 7; centromere of chromosome 7)
signals. As per Vysis guidelines, a ratio of greater than 3:2
orange to green signals was classified as denoting EGFR
positivity, and a ratio of 2 or greater was considered highly
amplified EGFR. Results were also analyzed using the
method of Cappuzzo et al.26 These authors categorized tu-
mors as follows: (1) disomy (two or fewer copies in90% of
cells); (2) low trisomy (two or fewer copies in 40% or more
of cells, three copies in 10-40% of cells, or four or more
copies in 10% of cells); (3) high trisomy (two or fewer
copies in 40% or more of cells, three copies in 40% or more
of cells, or four or more copies in 10% of cells); (4) low
polysomy (four or more copies in 10-40% of cells); (5) high
polysomy (four or more copies in 40% or more of cells); and
(6) gene amplification (EGFR gene clusters and a ratio of
EGFR gene to chromosome 7 of 2 or more or 15 or more
copies per cell in 10% or more of the cells).
EGFR Mutation Testing
Mutations in EGFR hot spots were analyzed by dide-
aoxy sequencing and pyrosequencing after laser capture mi-
crodissection. Cell lines (HELA, HepG2) were used as neg-
ative controls. Because no tested cell lines contained a
mutation in EGFR, samples were run in duplicate, and those
with a mutation were repeated. Concordance between results
was 100% (data not shown). Samples with identified muta-
tions were then used as positive controls in subsequent
experiments.
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Laser Capture Microdissection and DNA
Extraction
Laser capture microdissection was used to isolate tumor
cells from prepared slides for the analysis of EGFR muta-
tions. Semi-thin sections (8 m) were prepared from paraffin
blocks and mounted onto plain glass slides. After drying
overnight, slides were deparaffinized by successive xylene
and ethanol washes. Sections were laser microdissected using
a PixCell-II LCM system (Arcturus, Mountain View, Cali-
fornia). Approximately 1000 lung cancer cells were laser-
captured from each tissue specimen. According to the man-
ufacturer’s instructions, total DNA was extracted using the
PicoPure DNA Isolation Kit (Arcturus).
EGFR Mutations (Exons 18-21) In Tumor DNA
by Conventional Sequencing or
Pyrosequencing
Conventional DNA Sequencing (Dideoxy
Sequencing)
Dideoxy sequencing was used for detecting exon 19
deletions in EGFR. EGFR exon 19 was amplified with the
following primers (Biotechnology Center, University of Wis-
consin, Madison, WI), forward PCR primer: 5=-GTA ACA
TCC ACC CAG ATC AC-3= and reverse PCR primer:
5=-CAG AAA CTC ACA TCG AGG AT -3=. PCR products
were sequenced by a conventional capillary sequencer. The
sequence reaction was performed in 10-l volumes using a
Big Dye chemistry Kit (Perkin-Elmer Applied Biosystems
Division, Foster City, CA) according to the manufacturer’s
instructions. The sequences were determined with an ABI
Prism 310 automatic sequencer (Applied Biosystems). The
results were edited and analyzed with BioEdit version 5.0.3
(North Carolina State University, NC) and compared with the
human EGFR sequence (GenBank accession number
AY588246).
Sample Preparation for the Pyrosequencing
Reaction
Pyrosequencing was used as the major methodology for
detecting point mutations at positions 2573, 2582, and 2155
in EGFR. Exon 21 was amplified with the following PCR
primers (Biotechnology Center, University of Wisconsin),
forward PCR primer: 5=-Bio-CAG GGT CTT CTC TGT TTC
AG-3=
Reverse PCR Primer: 5=-ACC TAA AGC CAC CTC
CTT AC -3=
Biotinylated PCR products were immobilized on
streptavidin-coated Sepharose beads (Amersham Bio-
sciences, Clearbrook, IL). We added 50 l of binding buffer
(Pyrosequencing AB, Uppsala, Sweden) to 50 l of PCR
product; then 4 l of streptavidin-coated Sepharose beads
were added, and the solution was vigorously mixed at room
temperature for 10 minutes. The mixture was transferred to a
filter plate (Amersham Biosciences), and the binding buffer
was removed by vacuum. The biotinylated DNA attached to
the streptavidin-coated Sepharose beads was denaturated in
50 l of denaturation buffer (Pyrosequencing AB, Uppsala,
Sweden) for 1 minute. The denaturation buffer was removed
by vacuum, and the DNA was washed twice in 150 l of
Wash Buffer (Pyrosequencing AB). The ssDNA was resus-
pended in 50 l of annealing buffer (Pyrosequencing AB).
Pyrosequencing Reaction
The annealing reaction was performed at 80°C for 2
minutes on a thermoblock. The annealing mixture contained:
35 l of ssDNA suspension, 5 M sequencing primer:
5=-TTC TCT TCC GCA CCC-3= (Integrated DNA Technol-
ogies, Coralville, IA), 2 mM MgCl2. After the annealing
reaction, 4 l of SSB reagent (Pyrosequencing AB) was
added to the mixture. Pyrosequencing was performed at 30°C
in an automated 96-well Pyrosequencer instrument using a
PSQ™ 96 SQA Kit containing enzymes and substrates with
cyclic dispension of the nucleotides, according to the manu-
facturer’s instructions (Pyrosequencing AB). Pyrosequencing
data were evaluated using Peak Height Determination Soft-
ware v1.1 (Pyrosequencing AB) and compared with the
human EGFR sequence (GenBank accession number
AY588246).
Statistical Methods
Time to progression was calculated from the time of
treatment initiation to the time of progression or last follow-
up. Overall survival was calculated from the date of treatment
initiation to the date of death or last follow-up. Survival
curves were constructed using the Kaplan-Meier method.15
The log rank test was used to assess the significance of
univariate associations when the outcome of interest was time
to progression or survival. Fisher’s exact test was used to
compare groups with respect to dichotomous end points. For
most analyses, we compared patients with an objective re-
sponse or disease control with patients with progressive
disease. A linear  linear association test was used when
appropriate. Logistic regression analysis was performed to
evaluate associations between the dichotomized outcomes
(e.g., response) and covariates of interest. All p values re-
ported are two-sided. The data were analyzed by using SPSS
software (version 13.0; SPSS, Inc, Chicago, IL). Conditional
exact logistic regression analysis was conducted using LogX-
act version 4.1 (Cytel Software).
RESULTS
Of all the patients enrolled in the compassionate use
program, 43 (23%) with advanced NSCLC who had available
and sufficient material for laboratory studies and complete
clinical data were the subject of analysis for gefitinib efficacy.
Their characteristics are included in Table 1. Most were
female (58%), Caucasian (74%), and had adenocarcinoma
(58%). Twelve patients (28%) received gefitinib as first-line
therapy. As expected, because of a higher probability of
tumor specimen availability, a high proportion of our patients
(17 of 43) had previously undergone thoracic surgery for
earlier stage disease.
Molecular Marker Evaluation
The presence of molecular markers in tumors that were
assessed by each method is displayed in Table 2. We identi-
fied three EGFR mutations (9%) in 35 adequately tested
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tumors: one L747_T751,753 deletion in exon 19, one
E746_A750 deletion in exon 19, and one substitution in exon
21 (L858R), which have been described previously.15
We found that patients with EGFR mutations had
tumors with the highest EGFR gene copy numbers (p 
0.001) (Table 3). There was no identifiable relationship be-
tween EGFR IHC and FISH results in 27 tumors assessed by
both techniques (Table 4). However, there was a trend to-
wards an inverse correlation of AKT expression with EGFR
positivity by FISH (Table 4). Also, we did not detect any
significant correlation between the presence of a biomarker
and any clinical characteristics, except higher EGFR gene
copy numbers (ratio 1.5) in females (12/19) versus males
(3/13) (p  0.04).
Treatment Efficacy and Prognostic Factors
Six patients (14%) achieved a partial response (PR) and
9 patients (21%) achieved stable disease as best response of
total of 43 patients treated with gefitinib; the disease control
rate was 35%. Median time to progression was 70 days (95%
confidence interval 51-89), and median survival was 162 days
(95% confidence interval 105-219).
Patients with EGFR mutations (3 of 43) had either
stable disease (n  2) or PR (n  1). Of these three patients,
one was a Caucasian woman and former smoker; the other
two were Asian and had never smoked: a man with adeno-
carcinoma, who achieved a PR, and a woman with squamous
cell carcinoma, who had stable disease. Four of six PRs
achieved in this study were observed in patients who had
never smoked (p  0.028). Univariate analysis showed that
the following parameters were predictive of disease control:
TABLE 1. Patient characteristics (n  43)
Age in years, median (range) 65 (34–86)
Gender, No. (%)
Male 18 (42)
Female 25 (58)
Race, No. (%)
Caucasian 32 (74)
African-American 4 (9)
Asian 5 (12)
Other 2 (5)
Histology, No. (%)
Adenocarcinomaa 25 (58)
Squamous cell 5 (12)
Bronchioloalveolar 2 (5)
Large cell 3 (7)
Mixed 1 (2)
NSCLC, not otherwise specified 7 (16)
Performance status, No. (%)
0 8 (19)
1 11 (26)
2 9 (21)
3 6 (14)
4 1 (2)
Not reported 8 (19)
Previous chemotherapy, No. (%)
Yes 31 (72)
No 12 (28)
Previous radiation therapy, No. (%)
Yes 32 (72)
No 10 (23)
Unknown 1 (2)
Previous thoracic surgery, No. (%)
Yes 17 (39)
No 26 (51)
aOne case with bronchioloalveolar features. NSCLC, non–small-cell lung cancer.
TABLE 2. EGFR-related biomarkers in NSCLC
Positive tumors
Biomarker No. (%)
Immunohistochemistry
EGFR, n  35 20 (57)
pEGFR, n  42 16 (38)
AKT, n  41 16 (39)
pAKT, n  41 14 (34)
ERK, n  38 24 (63)
pERK, n  38 18 (47)
p38, n  41 13 (32)
pp38, n  25 40 (63)
EGFR FISH, n  32
Ratio 1.5 15 (47)
Ratio of 2 or more 4 (13)
High polysomy or amplificationa 4 (13)
EGFR mutation in exons 18-21, n  35 3 (9)
aAs reported in Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor
receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl
Cancer Inst 2005;97:643–655. Three of four cases with “ratio of 2 or more” were
categorized as “high polysomy or amplification.” Otherwise, there was concordance
between the two methods (27 samples were EGFR low and 3 EGFR high by both).
EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer.
TABLE 3. Correlation of EGFR mutations with EGFR gene
copy number and EGFR and AKT protein expression
Mutation
absent
Mutation
present Total
EGFR gene copy number by FISHa
EGFR low 24 0 24
EGFR high 1 3 4
p  0.001
EGFR by immunohistochemistry
EGFR () 11 0 11
EGFR () 16 2 18
p  0.51
AKT
AKT () 18 3 26
AKT () 13 0 17
p  0.27
aAs reported in Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor
receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl
Cancer Inst 2005;97:643–655. EGFR, epidermal growth factor receptor; FISH, fluo-
rescence in situ hybridization.
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no history of smoking (p  0.056), rash of any grade (p 
0.02), high levels of AKT expression (p  0.05), and the
presence of EGFR mutations (p  0.04) (Table 5). An even
stronger association between response (PR, stable disease, or
progression) and AKT IHC score (0-4) (p  0.0036), as
well as between response and rash (grade 0, 1, or 2) (p 
0.0095), was found using a linear linear association test. In
a logistic regression model that contained all four variables
(Table 6), rash and AKT retained an independent prognostic
significance.
The development of rash with gefitinib therapy was the
only statistically significant predictor of time to progression
and survival. The median survival of patients with rash (n 
15) was 368 days versus 79 days without rash (n  25) (p 
0.013; log rank) (Figure 1), and the median time to progres-
sion for patients with rash of any grade was 169 days versus
63 days for patients without rash (p  0.04; log rank).
Patients with high AKT expression (n  16) had a median
time to progression of 81 days versus 63 days for patients
with low AKT expression (n  25) (p  0.08) (Figure 2) and
a median survival of 175 days versus 156 days (p  0.2).
DISCUSSION
We observed that EGFR mutations are relatively rare in
patients with NSCLC in the United States and account for a
small fraction of the clinical activity of gefitinib. Accord-
ingly, recent reports show that the frequency of EGFR mu-
tation in American or European patients is relatively low, 10
to 13%19,21 or less.20 EGFR mutations have been correlated
with objective response and, more recently, with survival.22
Although all three of our patients with tumors harboring
EGFR mutations achieved disease control with gefitinib, only
one had a PR. Furthermore, the presence of an EGFR muta-
tion was identified in only 3 of 15 patients (20%) with an
objective response or stable disease (1 of 6 of patients with
PR). In studies conducted in Asia, NSCLC patients with
EGFR mutation-positive tumors represented a higher percent-
age of the responders. For example, 45% of Korean patients
who had PR or stable disease with gefitinib (52% of patients
with a PR) had tumors with an EGFR mutation.22
In accordance with the findings of other investigators,
we found that clinical parameters such as smoking status and
the development of rash were important predictors of ge-
fitinib efficacy. Rash is a class effect of EGFR inhibitors that
has been correlated with response and survival in various
tumor types.30–32 Pharmacodynamic changes in the skin of
patients undergoing treatment with EGFR inhibitors have
been proposed as surrogates of clinical efficacy.33–35 In our
study, rash has a major prognostic significance for gefitinib
therapy that is independent of other clinical and molecular
factors. Finally, smoking history has been proposed as a
predictor of outcome after EGFR-TKIs,36 and this observa-
tion was duplicated in our study. This may be partially
explained by the frequent presence of EGFR mutations in
patients who never smoked,18 possibly through an inverse
relationship with k-ras mutations (not evaluated in our
study).20,37,38 However, even in patients with NSCLC tumors
without EGFR mutations, those who never smoked may have
a favorable outcome with gefitinib therapy.22 In a recent
analysis of a placebo-controlled randomized trial of erlotinib,
Tsao et al.27 found that no smoking history and two other
factors (adenocarcinoma histology and either EGFR expres-
sion or EGFR polysomy/gene amplification) were signifi-
cantly associated with erlotinib responsiveness in multivari-
ate analysis.
The PI3K/AKT pathway is a critical mediator of sig-
naling via EGFR activation.28,39,40 To the best of our knowl-
edge, we are the first to report that high AKT expression was
associated with better disease control after gefitinib treat-
ment. It is likely that the status of AKT, a downstream
effector, is more important than the status of EGFR for
inactivation of EGFR signaling with gefitinib. Other investi-
gators have implicated the activated status of AKT (i.e.,
pAKT) as a predictor of response to gefitinib.22,41,42 Han et
al.22 reported that low pAKT is a favorable predictor of
response in patients with tumors without EGFR mutations. In
TABLE 4. EGFR gene copy number by FISH correlated with EGFR and AKT protein expression
EGFR gene copy number
using a cutoff ratio of 1.5 EGFR gene copy numbera
EGFR () EGFR () EGFR EGFR
(ratio of <1.5) (ratio >1.5) Low High
EGFR by IHC, n  27
EGFR () 6 4 10 0
EGFR () 8 9 14 3
p  0.69 p  0.27
AKT by IHC, n  30
AKT () 6 12 14 4
AKT () 9 3 12 0
p  0.06 p  0.13
aAs reported in Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity
in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643–655. EGFR, epidermal growth factor receptor; FISH, fluorescence in situ
hybridization; IHC, immunohistochemistry.
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contrast, tumors that are EGFR mutation-positive may de-
pend on signaling via PI3-K/AKT pathway; patients with
tumors with both EGFR mutations and high pAKT levels had
a favorable response to gefitinib.22 PAKT expression was
studied but was not found to be of prognostic value in our
study.
An intriguing observation is the suggested relationship
of the presence of EGFR mutations with gene amplification.
Laboratory data are also supportive of this assertion.43 A
large number of tumor samples will need to be studied to
conclusively evaluate this association. Cappuzzo et al.26 eval-
uated EGFR protein expression, pAKT, EGFR mutations,
and FISH in patients with NSCLC treated with gefitinib.
Similar to our findings, these investigators found a relation-
ship between EGFR gene amplification by FISH and muta-
tions, but contrary to our results, reported that high EGFR
gene copy number (seen in 33 of 102 patients), was the only
independent predictor of survival.26 Tsao et al.27 also found
that EGFR gene copy number was predictive of erlotinib
responsiveness and survival benefit from erlotinib. In their
analysis, patients with tumors with a high gene copy number
derived survival benefit from erlotinib (versus placebo), but
patients with tumors with a low gene copy number did not.
However, EGFR FISH status was not an independent predic-
tor of survival in the entire cohort of patients. In these two
studies26,27 and a previous study by Hirsch et al.,44 who found
TABLE 5. Univariate analysis of predictors of disease control
with gefitinib monotherapy (n  43)
Characteristic/biomarker
Disease control
(ORR  SD)
No. (%) p value*
Gender 0.52
Female 10/25 (40)
Male 5/18 (28)
Smoking history 0.056
Never smoker 6/10 (60)
Former or current smoker 7/29 (24)
Previous chemotherapy 0.72
No 5/12 (42)
Yes 10/31 (32)
Pathology 0.75
Adenocarcinoma or BAC 10/27 (37)
Other 5/16 (31)
Rash, n  39 0.02
Yes 9/15 (60)
No 5/24 (21)
EGFR by IHC, n  35 0.99
Positive 6/20 (30)
Negative 4/15 (27)
pEGFR, n  42 0.99
Positive 5/16 (31)
Negative 9/26 (35)
EGFR  by FISH, n  32
Positive (ratio 1.5) 6/15 (40) 0.71
Negative 5/17 (29)
High (ratio of 2 or above) 3/4 (75) 0.11
Low 8/28 (29)
Higha 3/4 (75) 0.11
Low 8/28 (29)
EGFR mutation status, n  35 0.04
Positive 3/3(100)
Negative 10/32 (31)
AKT, n  41 0.05
Positive 9/16 (56)
Negative 6/25 (24)
pAKT, n  41 0.30
Positive 7/14 (50)
Negative 8/27 (30)
ERK, n  38 0.30
Positive 7/24 (29)
Negative 6/14 (43)
pERK, n  38 0.41
Positive 7/18 (39)
Negative 6/20 (30)
P38, n  41 0.73
Positive 5/13 (38)
Negative 9/28 (32)
pP38, n  40 0.50
Positive 10/25 (40)
Negative 4/15 (27)
aAs reported in Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor
receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl
Cancer Inst 2005;97:643–655. EGFR, epidermal growth factor receptor; FISH, fluo-
rescence in situ hybridization; IHC, immunohistochemistry; ORR, objective response
rate; SD, stable disease rate; BAC, bronchoalveolar carcinoma. *Fisher’s exact test,
two-sided. The number of patient samples tested is listed in the first column.
TABLE 6. Exact logistic regression analysis model for
predicting disease control
Model term Beta
Lower
95% CI
Upper
95% CI
pvalue
(two-sided)
EGFR mutation 1.41 1.53 Inf 0.3429
Rash 2.39 0.14 Inf 0.0361
AKT 2.72 0.48 Inf 0.0152
Smoking 1.90 6.15 1.32 0.3467
EGFR, epidermal growth factor receptor; CI, confidence interval.
FIGURE 1. Kaplan-Meier survival curve of overall survival
according to the development of rash after gefitinib therapy.
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an association between EGFR by FISH and protein expres-
sion, investigators categorized NSCLC tumors as “high
copy” EGFR if they displayed high polysomy (defined as 4 or
more copies in 40% or more of the cells) or amplification
(high EGFR clusters and ratio of EGFR gene to chromosome
7 of 2 or more or 15 or more copies per cell in 10% or more
of the cells). In our analysis, we used both the normalized
ratio of EGFR copy number to chromosome 7 and the method
used by the above-referenced authors. Although we found
that patients with high EGFR gene copy number by either
method had higher disease control rates than patients with
low EGFR copy number (75% versus 29%), the difference
did not reach statistical significance, presumably because of
the relatively small number of cases.
Our data suggest that clinical and molecular character-
istics should be used in combination for the evaluation of
gefitinib efficacy. However, our retrospective analysis has a
number of limitations. Tissue acquisition was challenging
and, in many cases, paraffin-embedded tumor material was
not sufficient for determining all molecular markers. This is
consistent with the experience of other investigators.27 It is
also possible that our methodology was not sensitive enough
to detect existing mutations; thus, we may have underre-
ported the presence of EGFR mutations. The mutations we
did test for and detect, however, account for the vast majority
of EGFR mutations reported and have been strongly associ-
ated with gefitinib sensitivity based on biological as well as
clinical evidence.15,16 It is possible that different EGFR so-
matic mutations result in differential sensitivity to EGFR
blockade; in addition, acquired mutations that are associated
with resistance to EGFR-TKI have been described.45,46 Fi-
nally, our analysis of a relatively small number of patients
should be viewed as hypothesis-generating, and the associa-
tions reported as statistically significant will need to be
validated in future studies. Furthermore, because this was a
study of a single cohort of patients without a control, we
cannot ascertain whether the identified significant variables
are truly predictive or simply prognostic (i.e., independent of
therapy) of outcome. This distinction can only be achieved in
an analysis of a randomized, placebo-controlled trial, such as
the one recently reported for erlotinib.27 In conclusion, we
suggest that a combination of pretreatment factors (including
smoking history, AKT expression, and EGFR mutation sta-
tus), as well as the development of rash after treatment, can
be potentially used in combination to select patients with
NSCLC to receive gefitinib therapy. A comprehensive anal-
ysis of clinical and molecular characteristics should be pur-
sued in prospective clinical trials of EGFR inhibitors.
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